Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
AssigneeAvanir Pharmaceuticals
InventorsJohn F. Marcelletti, Laura E. Pope, Mohammed H. Khalil, David H. Katz, Lee R. Katz
Life of this patent
Estimating the term…
Abstract
The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically acceptable carrier. Methods for treating viral infections using such compositions are also disclosed.
Claims46
A synergistic antiviral composition, comprising a C21-C28 aliphatic alcohol, a nucleoside analog or nucleotide analog selected from the group consisting of acyclovir, adefovir, azidothymidine, brivudin, cidofovir, ddC, ddI, famciclovir, ganciclovir, idoxuridine, lamivudine, lobucavir, penciclovir, ribavirin, sorivudine, trifluridine, valaciclovir and Ara A, and a pharmaceutical acceptable carrier.
A composition for treatment or prophylaxis of a viral infection, comprising a mixture of n-docosanol and an antiviral agent selected from the group consisting of acyclovir, ribavirin, trifluridine and Ara A.
A method for treatment or prophylaxis of a viral infection, comprising administration of n-docosanol in conjunction with an antiviral agent selected from the group consisting of acyclovir, ribavirin, trifluridine, and Ara A.
A method for treatment or prophylaxis of a viral infection, comprising the administration of a synergistic combination of a C21-C28 aliphatic alcohol, and an antiviral agent selected from the group consisting of acyclovir, adefovir, azidothymidine, brivudin, cidofovir, ddC, ddI, famciclovir, ganciclovir, idoxuridine, lamivudine, lobucavir, penciclovir, ribavirin, sorivudine, trifluridine, valaciclovir and Ara A.
The method of 26, wherein the said aliphatic alcohol is erucyl alcohol, and the said antiviral agent is selected from the group consisting of acyclovir, ribavirin, trifluridine, and Ara A.
A method for treatment or prophylaxis of a viral infection, comprising the administration of a synergistic combination of n-docosanol, and an antiviral agent selected from the group consisting of acyclovir, adefovir, azidothymidine, brivudin, cidofovir, ddC, ddI, famciclovir, ganciclovir, idoxuridine, lamivudine, lobucavir, penciclovir, ribavirin, sorivudine, trifluridine, valaciclovir and Ara A.
Dependencies are inferred from the claim text.